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Three cases of infection by Staphylococcus
aureus with reduced susceptibility to the
glycopeptide antibiotics vancomycin and
teicoplanin (glycopeptide intermediate S. aureus,
GISA) have been reported from Japan,
Michigan, and New Jersey (1,2). We report the
third case in the United States of S. aureus with
reduced susceptibility to vancomycin. We found
that this GISA apparently emerged from a
methicillin-resistant  S. aureus (MRSA) isolate
that had infected/colonized the patient during
the 3 months before his death. This report
highlights key phenotypic characteristics of
interest to both clinicians and microbiologists.
The first (in New York State) S. aureus
isolate with reduced susceptibility to vancomy-
cin was obtained from the blood of a 79-year-old
man with a history of coronary artery disease,
obstructive pulmonary disease, hypothyroidism,
and renal failure requiring chronic hemodialy-
sis. Bacteremia developed in December 1997,
and an MRSA was isolated from the patients
blood on December 31. He received vancomycin
while in the hospital, improved clinically, and
was discharged. He was readmitted to the
hospital in January 1998 with an infected
jugular catheter, which was removed. An MRSA
isolate was obtained from the catheter on
January 10, and MRSA was also isolated from
the patients blood. He improved clinically and
was subsequently discharged on vancomycin
therapy. From December 1997 to February 1998
he received 3.5 g of intravenous vancomycin,
followed by a 7-day course of 3.5 g of oral
ciprofloxacin. In March 1998, the patient was
admitted to the dialysis center with signs of
congestive heart failure and sepsis and was
transferred to the hospital. He received
vancomycin (1 g), ceftriaxone (2 g), and
tobramycin (200 mg) but died the following day.
Over the last 4 months of his life, the patient
received 8.0 g of vancomycin for various infections
or for surgical prophylaxis of thrombectomy
repairs. An autopsy was not performed.
The vancomycin MIC of the isolate, obtained
from blood collected before the administration of
antibiotics on March 20 at the patients last
hospital admission, was determined by the
hospital laboratory to be 8 µg/ml by Etest (3) and
MicroScan conventional panels (Dade Behring,
Inc., MicroScan). This MIC was confirmed by
broth microdilution at the New York State
Department of Health and the Centers for
Disease Control and Prevention (4). The MRSA
isolates obtained from the patient in December
and January were susceptible to vancomycin by
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A  Staphylococcus aureus isolate with reduced susceptibility to vancomycin was
obtained from a dialysis patient with a fatal case of bacteremia. Comparison of the
isolate with two methicillin-resistant S. aureus (MRSA) isolates obtained from the same
patient 4 months earlier suggests that the S. aureus with reduced susceptibility to
vancomycin emerged from the MRSA strain with which the patient was infected.
Atypical phenotypic characteristics, including weak or negative latex-agglutination test
results, weak or negative-slide coagulase test results, heterogeneous morphologic
features, slow rate of growth, and vancomycin susceptibility (by disk diffusion test) were
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broth microdilution (MIC <2 µg/ml) and Etest
(3 µg/ml and 4 µg/ml, respectively). All three
isolates appeared to be susceptible to vancomy-
cin when tested by the disk diffusion method,
with zones of 17 mm to 18 mm (5), and were
susceptible to teicoplanin by broth microdilution
(MIC 2-4 µg/ml). Broth microdilution and Etest
results showed that in addition to vancomycin
and methicillin, the GISA isolate is also resistant
to penicillin, erythromycin, ciprofloxacin, and
rifampin; the two MRSA isolates from December
and January were also resistant to the latter four
antibacterial agents, although at higher levels
than the GISA isolate for penicillin (>32 µg/ml
and 6  µg/ml, respectively) and erythromycin
(256  µg/ml and 16 µg/ml, respectively). All three
isolates were susceptible to clindamycin,
trimethoprim/sulfamethoxazole, gentamicin,
chloramphenicol, and tetracycline. Although the
susceptibilities of the recently described GISA
isolates to antimicrobial agents vary, all are
resistant to clindamycin (6), whereas the GISA
isolate was susceptible.
The GISA isolate has two colony types, one of
which is smaller than the typical S. aureus
colony. The MRSA obtained from the patient in
January also demonstrated colony size heteroge-
neity, unlike the MRSA obtained in December,
which had only the larger typical colony type.
Coagulase activity of the GISA isolate was
detected at 24 hours by tube test but was only
very weakly detected by slide test (NYSDOH) or
was negative (UHMC, CDC). Atypical (weakly
positive [Staphyloslide, BBL] or negative
[Staphaurex, Murex]) results were obtained by
latex-agglutination tests.
As part of a contact investigation, cultures
were obtained from the nares and hands of
dialysis center and hospital employees, health-
care aides, dialysis center patients, and family
members. Nares of 45 persons and the hands of
19 of the 45 were cultured; 14 methicillin-
susceptible S. aureus (MSSA) and two MRSA
isolates (one from a nephrologist and one from a
dialysis patient) were obtained. However, no
other GISA isolates were found. There was no
evidence that the GISA was spread to other
patients or employees.
The  S. aureus isolates obtained from the
patient in December, January, and March, as
well as the MRSA from the nephrologist and the
dialysis patient, were compared by pulsed-field
gel electrophoresis (PFGE). The three isolates
from the patient had the same PFGE type
(Figure). The isolates from the nephrologist and
the dialysis patient (not shown) had PFGE types
unrelated to the GISA type and unrelated to each
other. This suggests that GISA emerged from the
MRSA strain that had infected the patient in
December, presumably as a result of vancomycin
therapy. Although the patient was admitted to
the hospital in March with a high fever and
evidence of pneumonia and the GISA isolate was
obtained from blood specimens during hospital-
ization, it was not possible to determine whether
vancomycin resistance in this organism was
responsible for the patients death.
The third reported in the United States, this
case of GISA is similar to previously reported
cases. The patient described above had been
infected with MRSA for several months and had
received prolonged treatment with vancomycin.
Laboratories should retain MRSA isolates
because they may be valuable in outbreak
investigations. As in this case, MRSA isolates,
together with subsequent isolates, can be used in
studying the emergence of glycopeptide resis-
Figure. Pulsed-field gel electrophoresis (PFGE) profiles
of  SmaI digested DNA. Case patient MRSA isolates
from December 1997 and January 1998, GISA isolate
from March 1998. Nephrologist MRSA isolate from
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tance in MRSA. The GISA isolate grew slowly,
had heterogeneous morphologic features, weak
or negative slide-coagulase test results, and
weak or negative latex-agglutination test
results. GISA appeared to be susceptible to
vancomycin by disk diffusion, as was reported for
the previous isolates (6). The disk diffusion test
does not appear to be accurate for determining
vancomycin susceptibility in these organisms.
Microbroth dilution or the Etest method should
be used instead. Atypical phenotypic character-
istics have been reported for every other GISA,
although not all isolates exhibited the same
atypical characteristics (1,2,6,7). Laboratorians
should be aware of these atypical characteristics
so that GISA are not misidentified. Evidence for
cell-wall reorganization has been reported for
GISA isolates (1,7). These changes in cell-wall
structure may be responsible for the atypical
phenotypic characteristics and decreased suscep-
tibility to vancomycin.
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